Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours

Gianluca Del Conte(IRCCS Ospedale San Raffaele), Luca Gianni(Fondazione Michelangelo)
British Journal of Cancer
July 15, 2014
10.1038/bjc.2014.345
Cited by 103

Related Papers

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
|Annals of Oncology|2022|382
30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study
|BMJ|2005|252
Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer
|Journal of Clinical Oncology|2009|216
Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy
|Clinical Cancer Research|2005|165